Hansen Pharmaceuticals was the primary carcinogen of betel nut because of its main product, Simotang, and Hansen Pharmaceutical resumed trading on the 27th. However, after the opening, it was directly hit by the daily limit, and the stock fell by 9.99% to 2.23 yuan at the close. Shares closed at 20.09 yuan/share. In addition to Hansen Pharmaceuticals, the company’s share price, which is related to betel nut, has fallen sharply.

Recently, the betel nut in the raw material of Simotang Oral Liquid, which is the leading product of Hansen Pharmaceuticals, was recognized by the World Health Organization (WHO) in 2003 as "a substance or a mixture with definitive carcinogenicity to the human body". However, the company did not reveal in the drug description. Betel nut carcinogenic risk. Hansen Pharmaceutical also suspended the suspension of the license the day before yesterday.

As of the time of press release, the Food and Drug Administration has not yet made an official response to the issue of "Simoyu decoction containing a class of carcinogen." However, the database of the State Food and Drug Administration website shows that there are 115 registration approvals for drugs with betel nut in the drug name. Among them are: Champagne Champagne Pills produced by Beijing Tong Ren Tang, Champagne Champagne Pills of China Resources Sanjiu Huangshi Pharmaceutical Co., Ltd., and Areca Essence Tablets of Harbin Pharmaceutical Group Sanhei Heihe Pharmaceuticals.

Or, affected by the incident of Hansen Sima Tang, on the 27th, the share price of companies that had a relationship with betel nuts had fallen sharply. For example, Tianjin Zhongxin Pharmaceutical Co., Ltd. has its products such as Areca Sixiao Pills and Champagne Pellets. The stock fell once yesterday, and finally closed at 13.43 yuan, down 9.87%. China Resources Sanjiu also fell 4.29% yesterday.